NVIDIA Survey Shows 70% of Healthcare Firms Now Deploy AI as ROI Hits Mainstream
Tony Kim Feb 24, 2026 14:42
NVIDIA's 2026 healthcare AI survey reveals adoption jumped to 70% from 63%, with 85% of executives reporting revenue gains and nearly half planning 10%+ budget increases.
Healthcare organizations have moved past the tire-kicking phase with artificial intelligence. NVIDIA's second annual State of AI in Healthcare and Life Sciences survey shows 70% of respondents now actively deploy AI in their operations, up from 63% in 2024—a 7-percentage-point jump that signals the technology has crossed from experimental to essential.
The money tells the story. A full 85% of surveyed executives said AI is helping increase revenue, while 80% reported cost reductions. Those aren't pilot program numbers—they're production returns.
Where the Dollars Are Flowing
Budget commitments reflect the confidence. Among respondents, 85% expect AI spending to rise this year, with 46% planning increases exceeding 10%. Only 3% anticipate cuts.
The survey breaks down ROI by sector. Medical technology companies report the clearest wins in imaging—57% cite measurable returns from AI-assisted radiology. Pharma and biotech firms point to drug discovery, where 46% see AI among their top ROI drivers. For payers and providers, the gains come from less glamorous territory: administrative tasks and workflow optimization topped their list at 39%.
"Over the next 12-18 months, the most visible and scalable impact of AI will come from logistics and administrative streamlining," said John Nosta, president of healthcare think tank NostaLab. "That's where adoption curves are already steep—scheduling, documentation, coding, utilization management and care coordination."
Generative AI Takes the Lead
The technology mix has shifted notably. Generative AI and large language models now rank as the top workload, cited by 69% of respondents—up sharply from 54% last year. Data analytics held second place, with predictive analytics third.
Agentic AI emerged as a new category this year, with 47% either using or evaluating AI agents for tasks like knowledge retrieval and research analysis. That's a substantial figure for technology that barely existed in enterprise healthcare 18 months ago.
Digital healthcare leads adoption rates at 78%, followed by medical technology at 74%. The survey covered pharmaceutical companies, biotechs, payers, providers, and medtech firms.
Open Source Gains Ground
Perhaps surprisingly for an industry obsessed with liability, 82% of respondents called open source software and models moderately to extremely important to their AI strategy. The appeal lies in customization—healthcare organizations can fine-tune models for domain-specific applications rather than relying on general-purpose tools.
"Open models will shape the intellectual field," Nosta noted. "But in clinical environments where safety, liability and accountability are nonnegotiable, proprietary systems will remain necessary for validation, integration and trust."
The trajectory here matters for investors watching NVIDIA's healthcare vertical. Morgan Stanley data from 2023 showed healthcare companies allocating 5.7% of budgets to AI/ML, with projections targeting 10.5% by 2024. The NVIDIA survey suggests those forecasts may have undershot reality. With nearly half of organizations planning double-digit budget increases, the healthcare AI market—valued between $1.3 billion and $2 billion in 2023—appears headed for accelerated growth through 2033.
Image source: Shutterstock- nvda
- healthcare ai
- drug discovery
- medical imaging
- enterprise ai
